1. Home
  2. STOK vs WSR Comparison

STOK vs WSR Comparison

Compare STOK & WSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STOK
  • WSR
  • Stock Information
  • Founded
  • STOK 2014
  • WSR 1998
  • Country
  • STOK United States
  • WSR United States
  • Employees
  • STOK N/A
  • WSR N/A
  • Industry
  • STOK Biotechnology: Pharmaceutical Preparations
  • WSR Real Estate Investment Trusts
  • Sector
  • STOK Health Care
  • WSR Real Estate
  • Exchange
  • STOK Nasdaq
  • WSR Nasdaq
  • Market Cap
  • STOK 740.9M
  • WSR 628.6M
  • IPO Year
  • STOK 2019
  • WSR 2010
  • Fundamental
  • Price
  • STOK $12.87
  • WSR $12.38
  • Analyst Decision
  • STOK Strong Buy
  • WSR Strong Buy
  • Analyst Count
  • STOK 5
  • WSR 2
  • Target Price
  • STOK $27.75
  • WSR $15.00
  • AVG Volume (30 Days)
  • STOK 763.5K
  • WSR 210.3K
  • Earning Date
  • STOK 08-06-2025
  • WSR 07-30-2025
  • Dividend Yield
  • STOK N/A
  • WSR 4.29%
  • EPS Growth
  • STOK N/A
  • WSR 26.93
  • EPS
  • STOK 0.88
  • WSR 0.61
  • Revenue
  • STOK $190,908,000.00
  • WSR $155,128,000.00
  • Revenue This Year
  • STOK $378.84
  • WSR $2.00
  • Revenue Next Year
  • STOK N/A
  • WSR $5.14
  • P/E Ratio
  • STOK $14.68
  • WSR $20.69
  • Revenue Growth
  • STOK 2333.81
  • WSR 6.69
  • 52 Week Low
  • STOK $5.35
  • WSR $11.78
  • 52 Week High
  • STOK $16.15
  • WSR $15.36
  • Technical
  • Relative Strength Index (RSI)
  • STOK 55.63
  • WSR 45.59
  • Support Level
  • STOK $12.25
  • WSR $12.36
  • Resistance Level
  • STOK $14.99
  • WSR $12.64
  • Average True Range (ATR)
  • STOK 0.83
  • WSR 0.23
  • MACD
  • STOK -0.04
  • WSR -0.01
  • Stochastic Oscillator
  • STOK 36.30
  • WSR 10.64

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

About WSR Whitestone REIT

Whitestone REIT is a real estate investment trust (REIT) engaged in owning and operating commercial properties in culturally diverse markets in metropolitan areas. The company's primary business objective is to increase shareholder value by acquiring, owning, and operating Community Centered Properties. Its property portfolio includes retail and mixed-use properties located in business friendly locations in and around Austin, Chicago, Dallas-Fort Worth, Houston, Phoenix, and San Antonio. The properties are convenience-focused: merchandised with a mix of service-oriented tenants providing food (restaurants and grocers), self-care (health and fitness), services (financial and logistics), education, and entertainment to the surrounding communities.

Share on Social Networks: